IQVIA Holdings Inc. (IQV) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

MIXED

IQVIA Holdings (IQV) traded lower despite reporting in-line financial results, with AI-related market fears cited as the primary driver for the decline. This suggests that broader sector anxieties are currently overshadowing the company's operational performance. IQV, which provides clinical research and healthcare intelligence services, is facing a market environment where concerns about artificial intelligence are impacting investor sentiment. Investors will be watching to see if these AI-related fears continue to weigh on IQV or if the company's fundamental business can regain focus.

Market Data

IQV Stock Snapshot

IQVIA Holdings Inc. · Healthcare · iqvia.com

IQVIA Holdings, Inc. is a global provider of technology, analytics, and services to the life sciences and healthcare industries. The company's core value proposition lies in its ability to offer comprehensive solutions across the drug development and commercialization lifecycle. IQVIA operates through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, each contributing to its integrated offerings. These solutions help clients with clinical trial support, data-driven insights for healthcare decision-making, and commercialization strategies. Serving pharmaceutical, biotechnology, and medical device companies, IQVIA is strategically positioned to support the evolving needs of the healthcare sector.

IQV is currently trading at $179.96, giving IQVIA Holdings Inc. a market cap of 29.95B and a P/E ratio of 22.0. Today's range spans $173.61–$179.96, with shares opening at $174.40 and moving up $3.56 (2.0%) from the prior close. DailyIQ's technical score sits at 73/100 (BUY) with a news sentiment reading of 50/100.

Over the past year IQV has traded between $134.65 and $247.05 - the current price is +33.7% off the 52-week low and -27.2% from the high. 33 analysts cover the stock with a Buy consensus and a mean 12-month target of $231.60 (range $185.00–$287.00), implying upside of +28.7%.

IQVIA Holdings Inc. (IQV) is a large-cap in Healthcare with 29.95B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 73/100 (BUY). Sentiment: neutral at 50/100. Price: $179.96 (in the lower half of its 52-week range). The current P/E ratio stands at 22.0. The 52-week range of $134.65–$247.05 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

IQV|EarningsIQVIA Holdings Inc.

Earnings Summary

IQVIA Holdings, Inc. is a significant player in the Healthcare sector, specifically within the Diagnostics & Research industry, providing technology, analytics, and services to life sciences and healthcare organizations. The company's integrated solutions span the entire drug development and commercialization lifecycle, encompassing clinical trial support, data-driven insights, and commercialization strategies through its Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions segments. IQVIA serves pharmaceutical, biotechnology, and medical device companies, positioning itself to address the evolving demands of the healthcare landscape. In its recent quarterly performance, IQVIA has shown a consistent pattern of meeting or slightly exceeding analyst expectations. For Q4 2025, the company reported actual EPS of $3.12 against an estimate of $3.10883, with revenue at $3.958 billion. This followed Q3 2025, where actual EPS was $3.00 versus an estimate of $2.97588, and revenue was $4.100 billion. The prior two quarters, Q2 2025 and Q1 2025, saw actual EPS of $2.81 and $2.70, against estimates of $2.77039 and $2.63225 respectively, with revenues of $4.017 billion and $3.829 billion. This indicates a steady trend of EPS beats in the last four reported quarters, with revenue estimates not provided for earlier periods. Historically, IQVIA has demonstrated a strong beat rate against analyst EPS estimates, suggesting reliable operational execution and forecasting. The company has consistently delivered earnings above expectations, reinforcing its stable performance. Recent news indicates IQVIA's launch of IQVIA.ai, a new platform developed with NVIDIA to integrate artificial intelligence into life sciences workflows, aiming to accelerate research and improve efficiency. Despite this innovation, the stock has seen downward pressure attributed to broader AI-related market fears, suggesting that sector-wide sentiment is currently impacting investor perception. Early prescription data for Eli Lilly's new drug, Foundayo, utilizing IQVIA data, offers a glimpse into initial market penetration. Looking ahead, investors will be watching for the continued adoption and impact of the IQVIA.ai platform, the sustained growth of new drug prescriptions tracked by IQVIA, and how broader market sentiment regarding AI evolves in relation to the company's fundamental business performance.

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$2.82	-	-
Q3'25	$2.98	$3.00	+0.8%
Q2'25	$2.77	$2.81	+1.4%
Q1'25	$2.63	$2.70	+2.6%
Q4'24	$3.11	$3.12	+0.4%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$4.1B	-	-
Q3'25	-	$4.1B	-
Q2'25	-	$4.0B	-
Q1'25	-	$3.8B	-
Q4'24	-	$4.0B	-

Technical Score (1D)

BUY

News Sentiment

MIXED

Market Data

IQV Stock Snapshot

IQVIA Holdings Inc. · Healthcare · iqvia.com

News Sentiment Analysis

Sentiment gathered from recent headlines

50/100

Strong NegativeNeutralStrong Positive

MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

IQVIA data indicates that Eli Lilly's new drug, Foundayo, recorded 1,390 prescriptions for the week ending April 10. This figure was shared by an analyst, highlighting the early uptake of the medication. The data provides a snapshot of the drug's initial market penetration.

What did this article say?

IQVIA Holdings Inc. has scheduled the release of its first-quarter 2026 financial results for Tuesday, May 5, 2026, prior to market open. Management will subsequently host a conference call and webcast at 9:00 a.m. Eastern Time to discuss the results. Investors can access the earnings release and financial information on the company's Investor Relations website.

What did this article say?

IQVIA Holdings (IQV) experienced a stock decline despite reporting results in line with expectations. This downward pressure appears to be driven by broader market concerns related to artificial intelligence, overshadowing the company's operational performance. The stock's recent performance shows a modest one-month gain but a more significant increase over the past 52 weeks.

What did this article say?

IQVIA Holdings (IQV) is scheduled to report its first quarter financial results soon. Current analyst consensus anticipates a single-digit increase in the company's profitability for the period. This earnings release will provide key insights into the company's performance and outlook.

What did this article say?

IQVIA Holdings is identified as a strong value stock, supported by its long-term earnings growth projections. The company is expected to achieve significant year-over-year EPS increases in the coming years. This outlook suggests potential for continued financial performance and investor returns.

What did this article say?

IQVIA's strategic collaboration with NVIDIA to launch IQVIA.ai is enhancing AI adoption in life sciences workflows, aiming to boost efficiency and decision-making. While this AI push and ongoing buybacks are driving growth, a recent dip in liquidity warrants attention regarding the company's near-term financial flexibility.

What did this article say?

IQVIA Holdings (IQV) is identified as a strong momentum stock, indicating robust investor interest and positive market perception. This classification suggests that the company's stock is experiencing sustained upward price movement, driven by factors likely including strong financial performance or positive industry outlook. Traders should monitor continued price action and any accompanying fundamental catalysts that may be fueling this trend.

What did this article say?

Evercore ISI has adjusted its price target for IQVIA Holdings (IQV) from $225 to $185, while reiterating an 'Outperform' rating. This move suggests a recalibration of near-term valuation expectations by the analyst firm. The stock's consensus rating remains positive, indicating underlying analyst confidence despite the target adjustment.

What did this article say?

Evercore ISI Group analyst Elizabeth Anderson has reiterated an Outperform rating on IQVIA Holdings (IQV). However, the firm has lowered its price target for the stock from $225 to $185. This adjustment suggests a recalibration of valuation expectations while maintaining a positive outlook on the company's prospects.

What did this article say?

Baird has adjusted its price target for IQVIA Holdings (IQV) downwards from $243 to $230, while maintaining an 'Outperform' rating. This analyst action suggests continued confidence in the company's prospects despite a revised valuation. The average rating among analysts remains 'buy' with a mean price target around $232.20.

IQV|EarningsIQVIA Holdings Inc.

Earnings Summary

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$2.82	-	-
Q3'25	$2.98	$3.00	+0.8%
Q2'25	$2.77	$2.81	+1.4%
Q1'25	$2.63	$2.70	+2.6%
Q4'24	$3.11	$3.12	+0.4%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$4.1B	-	-
Q3'25	-	$4.1B	-
Q2'25	-	$4.0B	-
Q1'25	-	$3.8B	-
Q4'24	-	$4.0B	-

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

IQV·IQVIA Holdings Inc.

IQV Stock Snapshot

Earnings | EPS

Revenue

IQV·IQVIA Holdings Inc.

IQV Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

News Sentiment Analysis

Recent News Coverage

IQV·IQVIA Holdings Inc.

IQV Stock Snapshot

Earnings | EPS

Revenue

IQV·IQVIA Holdings Inc.

IQV Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More